Armata Pharmaceuticals Inc


Prices are adjusted according to historical splits.

Armata Pharmaceuticals Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$96.14 million
Book Value:
Revenue TTM:
$5.45 million
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Armata Pharmaceuticals Inc had its IPO on 2011-03-09 under the ticker symbol ARMP.

The company operates in the Healthcare sector and Biotechnology industry. Armata Pharmaceuticals Inc has a staff strength of 69 employees.

Stock update

Shares of Armata Pharmaceuticals Inc opened at $1.77 at the start of the last trading session i.e. 2023-03-23.

The stocks traded within a range of $1.46 - $1.77, and closed at $1.55.

This is a -6.06% slip from the previous day's closing price.

A total volume of 20,300 shares were traded at the close of the day’s session.

In the last one week, shares of Armata Pharmaceuticals Inc have slipped by -6.63%.

Armata Pharmaceuticals Inc's Key Ratios

Armata Pharmaceuticals Inc has a market cap of $96.14 million, indicating a price to book ratio of 1.5068 and a price to sales ratio of 11.15.

In the last 12-months Armata Pharmaceuticals Inc’s revenue was $5.45 million with a gross profit of $-15541000 and an EBITDA of $-31742000. The EBITDA ratio measures Armata Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Armata Pharmaceuticals Inc’s operating margin was -599.82% while its return on assets stood at -30.12% with a return of equity of -94.18%.

In Q3, Armata Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 7%.

Armata Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-1.14 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Armata Pharmaceuticals Inc’s profitability.

Armata Pharmaceuticals Inc stock is trading at a EV to sales ratio of 148.1376 and a EV to EBITDA ratio of -2.6079. Its price to sales ratio in the trailing 12-months stood at 11.15.

Armata Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$92.88 million
Total Liabilities
$7.00 million
Operating Cash Flow
Capital Expenditure
$1.53 million
Dividend Payout Ratio

Armata Pharmaceuticals Inc ended 2023 with $92.88 million in total assets and $0 in total liabilities. Its intangible assets were valued at $92.88 million while shareholder equity stood at $45.58 million.

Armata Pharmaceuticals Inc ended 2023 with $10.26 million in deferred long-term liabilities, $7.00 million in other current liabilities, 361000.00 in common stock, $-229460000.00 in retained earnings and $3.49 million in goodwill. Its cash balance stood at $25.38 million and cash and short-term investments were $25.38 million. The company’s total short-term debt was $2,223,000 while long-term debt stood at $0.

Armata Pharmaceuticals Inc’s total current assets stands at $33.25 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $1.87 million compared to accounts payable of $7.86 million and inventory worth $0.

In 2023, Armata Pharmaceuticals Inc's operating cash flow was $-1294000.00 while its capital expenditure stood at $1.53 million.

Comparatively, Armata Pharmaceuticals Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Armata Pharmaceuticals Inc stock is currently trading at $1.55 per share. It touched a 52-week high of $5.79 and a 52-week low of $5.79. Analysts tracking the stock have a 12-month average target price of $8.

Its 50-day moving average was $2.51 and 200-day moving average was $3.12 The short ratio stood at 1.43 indicating a short percent outstanding of 0%.

Around 7306.6% of the company’s stock are held by insiders while 376.3% are held by institutions.

Frequently Asked Questions About Armata Pharmaceuticals Inc

The stock symbol (also called stock or share ticker) of Armata Pharmaceuticals Inc is ARMP

The IPO of Armata Pharmaceuticals Inc took place on 2011-03-09

Similar Industry Stocks (Biotechnology)

Last Price
Enbridge Inc (EBGEF)
Clarivate Plc (CLVT-PA)

Most Active

Last Price
Boxed Inc (BOXD)
Tesla Inc (TSLA)

Top Gainers

Last Price

Top Losers

Last Price
Imara Inc (IMRA)


Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company’s product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.


4503 Glencoe Avenue, Marina del Rey, CA, United States, 90292